Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Martin Shkreli, former CEO of Turing Pharmaceuticals, appearing before the House Committee on Oversight and Government Reform during a hearing titled “Developments in the Prescription Drug Market,” on Feb. 4, 2016. Photo: Diego M. Radzinschi/ALM

The biopharmaceutical company co-founded by convicted stock fraudster Martin Shkreli has lost its bid to depose the executive of a generic pharmaceutical company in connection with an antitrust lawsuit, and a Philadelphia federal judge has ordered it to pay the executive’s legal bill.

Want to continue reading?
Become a Free ALM Digital Reader.

Benefits of a Digital Membership:

  • Free access to 3 articles* every 30 days
  • Access to the entire ALM network of websites
  • Unlimited access to the ALM suite of newsletters
  • Build custom alerts on any search topic of your choosing
  • Search by a wide range of topics

*May exclude premium content
Already have an account?

Law Firms Mentioned


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.